Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena Ready For Etrasimod Phase III Face-Off With Celgene's Ozanimod In UC

Executive Summary

With significant Phase II results in ulcerative colitis, Arena is planning a Phase III program for its selective S1P receptor modulator etrasimod – a drug that it thinks can best Celgene's S1P-targeting therapy ozanimod on safety and possibly efficacy.

Advertisement

Related Content

Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate
Celgene's Focus On Execution Pays Off, But Follow-Through Is Key
On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study
Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Xeljanz's UC Indication On Track With Higher Doses After Unanimous Advisory Committee Votes
Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH
Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel